CAJ | 학술논문

目前大部分肺癌患者就诊时已是晚期，不宜手术切除，主要采用放疗、化疗和靶向治疗等综合治疗，5年生存率较低。免疫检查点阻断剂通过调整机体的免疫系统功能，打破肿瘤细胞免疫逃逸机制，使T细胞活化并清除肿瘤细胞，成为一种有效的肿瘤治疗方式。目前免疫检查点阻断剂在非小细胞肺癌（non-small cell lung cancer，NSCLC）临床试验中取得一定疗效，很多研究正在开展，这有可能改变NSCLC的治疗模式。本文将阐述免疫检查点阻断剂在NSCLC中的治疗作用及联合其他治疗的应用前景。
목전대부분폐암환자취진시이시만기，불의수술절제，주요채용방료、화료화파향치료등종합치료，5년생존솔교저。면역검사점조단제통과조정궤체적면역계통공능，타파종류세포면역도일궤제，사T세포활화병청제종류세포，성위일충유효적종류치료방식。목전면역검사점조단제재비소세포폐암（non-small cell lung cancer，NSCLC）림상시험중취득일정료효，흔다연구정재개전，저유가능개변NSCLC적치료모식。본문장천술면역검사점조단제재NSCLC중적치료작용급연합기타치료적응용전경。
In China, most patients with non-small cell lung cancer (NSCLC) were diagnosed with advanced or metastatic disease on first admission. These patients were treated by chemotherapy, radiotherapy, or targeted therapy. However, the 5-year overall survival rate is still low. Immunocheckpoint blockades adjust the immune function, dispatch immune escape, enhance T cell activation, and kill tumor cells. Immunocheckpoint blockade becomes one of the important methods of anti-tumor treatments. This approach may also change the model of NSCLC treatment because of its promising anti-tumor activity. This review summarizes the clinical trials on immu-nocheckpoint blockades in NSCLC and the possibility of combining this technique with other treatments.